Predictive value of FCGBP expression for treatment response and survival in rectal cancer patients undergoing chemoradiotherapy

Q: What is the purpose of evaluating FCGBP in rectal cancer patients undergoing CRT?

The study aims to determine whether FCGBP expression can predict treatment response and survival outcomes in rectal cancer patients receiving chemoradiotherapy.

Q: How was FCGBP identified as related to CRT resistance?

FCGBP was found as the most upregulated gene associated with CRT resistance through analysis of a public transcriptome dataset of 46 patients.

Q: What did immunohistochemical results show about FCGBP expression and patient outcomes?

Higher FCGBP immunointensity correlated with adverse clinicopathologic features and was linked to inferior disease-specific survival, local recurrence-free survival, and metastasis-free survival; it remained an unfavorable independent prognostic factor in multivariate analysis.

Sep 21, 2026

Uploaded by Ivy

Despite neoadjuvant chemoradiotherapy (CRT) being a standard for advanced rectal cancer, clinical outcomes remain insufficient, creating a need for predictive biomarkers. This study analyzed a public transcriptome of 46 rectal cancer patients and identified FCGBP as the most upregulated gene linked to CRT resistance. Immunohistochemistry in 343 tissue blocks showed that higher FCGBP immunointensity related to multiple clinicopathologic features and worse survival metrics, supporting FCGBP as an unfavorable independent prognostic biomarker.

LanguageEnglish

CategoryResearch & Report

FormatPDF

Pages13

Reading Time33 min

AccessFree to download

Abstract

Introduction

Background of rectal cancer and CRT

Rationale for FCGBP as a biomarker

[www.aging-us.com](www.aging-us.com) AGING 2024, Vol. 16, No. 9 Research Paper Predictive value of FCGBP expression for treatment response and survival in rectal cancer patients undergoing chemoradiotherapy Yu-Ting Su1, Chung-Hsing Chen2, Jui-Wen Kang3, Hsin-Yu Kuo3,4, Ching-Chieh Yang5,6, Yu-Feng Tian7, Cheng-Fa Yeh8,9, Chia-Lin Chou7,10, Shang-Hung Chen1,11 1 Department of Oncology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan 70456, Taiwan 2 National Institute of Cancer Research, National Health Research Institutes, Zhunan 35053, Taiwan 3 Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan 70456, Taiwan 4 Institute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan 70101, Taiwan 5 Department of Radiation Oncology, Chi Mei Medical Center, Tainan 71004, Taiwan 6 Department of Pharmacy, Chia-Nan University of Pharmacy and Science, Tainan 71710, Taiwan 7 Division of Colon and Rectal Surgery, Department of Surgery, Chi Mei Medical Center, Tainan 71004, Taiwan 8 Division of General Internal Medicine, Chi Mei Medical Center, Tainan 710, Taiwan 9 Department of Environment Engineering and Science, Chia Nan University of Pharmacy and Science, Tainan 71710, Taiwan 10 Department of Medical Technology, Chung Hwa University of Medical Technology, Tainan 71703, Taiwan 11 National Institute of Cancer Research, National Health Research Institutes, Tainan 70456, Taiwan Correspondence to: Chia-Lin Chou, Shang-Hung Chen; email: [991101@mail.chimei.org.tw](991101@mail.chimei.org.tw), [bryanchen@nhri.edu.tw](bryanchen@nhri.edu.tw)[ ](bryanchen@nhri.edu.tw)[Keywords:](Keywords: FCGBP)[ FCGBP](Keywords: FCGBP), rectal cancer, chemoradiotherapy Received: January 2, 2024 Accepted: March 26, 2024 Published: May 3, 2024 Copyright: © 2024 Su et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. ABSTRACT Despite neoadjuvant chemoradiotherapy (CRT) being the established standard for treating advanced rectal cancer, clinical outcomes remain suboptimal, necessitating the identification of predictive biomarkers for improved treatment decisions. Previous studies have hinted at the oncogenic properties of the Fc fragment of IgG binding protein (FCGBP) in various cancers; however, its clinical significance in rectal cancer remains unclear. In this study, we first conducted an analysis of a public transcriptome comprising 46 rectal cancer patients. Focusing on cell adhesion during data mining, we identified FCGBP as the most upregulated gene associated with CRT resistance. Subsequently, we assessed FCGBP immunointensity using immunohistochemical staining on 343 rectal cancer tissue blocks. Elevated FCGBP immunointensity correlated with lymph node involvement before treatment (p = 0.001), tumor invasion, and lymph node involvement after treatment (both p < 0.001), vascular invasion (p = 0.001), perineural invasion (p = 0.041), and reduced tumor regression (p < 0.001) . Univariate analysis revealed a significant association between high FCGBP immunoexpression and inferior disease-specific survival, local recurrence-free survival, and metastasis-free survival (all p ≤ 0.0002) . Furthermore, high FCGBP immunoexpression independently emerged as an unfavorable prognostic factor for all three survival outcomes in the multivariate analysis (all p ≤ 0.025) . Enriched pathway analysis substantiated the role of FCGBP in conferring resistance to radiation. In summary, our findings suggest that elevated FCGBP immunoexpression in rectal cancer significantly correlates with a poor response to CRT and diminished patient survival. FCGBP holds promise as a valuable prognostic biomarker

FAQs

What is the purpose of evaluating FCGBP in rectal cancer patients undergoing CRT?

The study aims to determine whether FCGBP expression can predict treatment response and survival outcomes in rectal cancer patients receiving chemoradiotherapy.

How was FCGBP identified as related to CRT resistance?

FCGBP was found as the most upregulated gene associated with CRT resistance through analysis of a public transcriptome dataset of 46 patients.

What did immunohistochemical results show about FCGBP expression and patient outcomes?

Higher FCGBP immunointensity correlated with adverse clinicopathologic features and was linked to inferior disease-specific survival, local recurrence-free survival, and metastasis-free survival; it remained an unfavorable independent prognostic factor in multivariate analysis.

Sep 21, 2026

Uploaded by Ivy